Next 10 |
2024-04-23 06:58:24 ET More on Danaher Danaher: All In On Life Sciences, And Market Update Danaher Corporation (DHR) TD Cowen 44th Annual Health Care Conference (Transcript) Danaher: Better Positioned For The Future Danaher Non-GAAP EPS of $1.92 beats by $0.2...
2024-04-22 12:53:43 ET More on S&P 500 Index: Fed's Commercial Banking Report Shows Economic Headwinds, But Deposit Growth Bucks Trend S&P 500: Capitulation? Week Starting 22nd April (Technical Analysis) Powell Playing Games: 'Sell In May' Is Now 'Sell Before...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conf...
2024-04-14 01:23:10 ET Summary Bio-Rad is a "picks and shovels" company in the life sciences industry, but lacks standout growth, margins, or returns, and that has been largely true for more than two decades. Recent trends in the life sciences space have been challenging, driving,...
2024-04-11 18:15:15 ET More on Bio-Rad Labs, OncoCyte, etc. Bio-Rad Laboratories, Inc. (BIO) Q4 2023 Earnings Call Transcript Bio-Rad Labs Q4 2023 Earnings Preview Danaher, Repligen rise as German peer Sartorius beats in Q4 Seeking Alpha’s Quant Rating...
- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (...
2024-04-11 10:33:00 ET The S&P 500’s health care sector ( NYSEARCA: XLV ), holding a weightage of 12.12% in the S&P 500 index, saw only a 3.82% rise YTD and is the third lowest scored sector by the SA Quant rating system.... Read the full article on Seeking Alph...
2024-04-10 16:25:35 ET More on Bio-Rad Labs Bio-Rad Labs Q4 2023 Earnings Preview Danaher, Repligen rise as German peer Sartorius beats in Q4 Seeking Alpha’s Quant Rating on Bio-Rad Labs Historical earnings data for Bio-Rad Labs Read the full...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of ...
2024-04-10 11:58:51 ET More on Estee Lauder, Hasbro, etc. Paramount Global's Sale Will Not Be Easy, Cheap, Or Fast Paramount: What The Skydance Proposal Means For Investors Paramount: Apollo Coming Around The Turn Ready To Pounce If Skydance Deal Falters ...
News, Short Squeeze, Breakout and More Instantly...
Bio-Rad Laboratories Inc. Class A Company Name:
BIO Stock Symbol:
NYSE Market:
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conf...
- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of ...